Loading clinical trials...
Loading clinical trials...
A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma
Conditions
Locations
58
United States
Research Site
Little Rock, Arkansas, United States
Research Site
Glendale, California, United States
Research Site
Los Angeles, California, United States
Research Site
Los Angeles, California, United States
Research Site
Monterey, California, United States
Research Site
Santa Rosa, California, United States
Start Date
January 17, 2019
Primary Completion Date
January 12, 2022
Completion Date
May 25, 2023
Last Updated
February 22, 2024
NCT06857175
NCT04693377
NCT04895709
NCT06948552
NCT07061964
NCT05987241
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions